Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 5 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Yesterday
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Early puberty onset in females predicts depression, antisocial behaviours in adulthood

13 Jan 2018

Early onset of puberty in young females results in higher rates of antisocial behaviour and depression, which persist into adulthood, a recent study has found.

The study included 7,802 females who were assessed for depressive symptoms and antisocial behaviours using self-reported questionnaires administered over five follow-up waves. Ordinary least-squares regression models were used to determine the relationship between the mental health symptoms and age at menarche.

According to the proximal influences model, early puberty onset was significantly and linearly predictive of depressive symptoms. That is, later ages of menarche were significantly correlated with lower symptom levels (p<0.05).

The researchers also found a borderline significant quadratic association between the two variables (p=0.09), indicating that earlier menarche may have compounding effects on later depressive symptoms.

Notably, the lingering influences model showed that earlier age of menarche was significantly associated with depressive symptoms both linearly (p<0.05) and quadratically (p<0.05) at the final follow-up. This suggests that young women who mature earlier are significantly more prone to depressive symptoms later in adulthood.

The trends were similar for antisocial behaviours. The proximal influences model revealed a significant and linear association between early maturation and the frequency of antisocial behaviour (p<0.05).

This relationship remained significant longitudinally (p<0.05) and even after controlling for adolescent levels of antisocial behaviours.

“The current research suggests that the sequelae of earlier development are not transient growing pains but are predictive of difficulties and challenges that persist into adulthood,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 5 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Yesterday
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.